Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Wrong potency or content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk.

992 FDA drug recalls with this cause, newest first.

These recalls cover sub-potent or super-potent products, or a failed content-uniformity test - meaning some pills in the same batch held noticeably different amounts of active ingredient than others. Either way it is a direct dosing risk: too little to work, or too much and harmful. Thyroid hormones and compounded injectables are the classic examples, because their dose window is narrow.

Class II · Moderate risk

Medline Wound Closure Tray

Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.

Terminated Wrong potency / content Medline Industries Inc D-0270-2018
Class II · Moderate risk

Medline Sheath Removal Kit

Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.

Terminated Wrong potency / content Medline Industries Inc D-0269-2018
Class II · Moderate risk

Medline I&D Tray Kit

Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.

Terminated Wrong potency / content Medline Industries Inc D-0268-2018
Class II · Moderate risk

Medline IV Start Kit

Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.

Terminated Wrong potency / content Medline Industries Inc D-0265-2018
Class II · Moderate risk

Medline TRAY

Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.

Terminated Wrong potency / content Medline Industries Inc D-0263-2018
Class II · Moderate risk

Medline Trunk Kit

Subpotent Drug:The titratable iodine contained in the Povidone-Iodine prep pads is below label claim of 0.85%.

Terminated Wrong potency / content Medline Industries Inc D-0262-2018
Class II · Moderate risk

Urin D/S Tablets Methenamine 81.6 mg

Superpotent Drug: Subpotent Drug. FDA analysis found this product to be Out of Specification for assay which could result in either Subpotent and/or Superpotent tablets.

Terminated Wrong potency / content Llorens Pharmaceutical Corp. D-0081-2018